SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class.

ABSTRACT:

Background

For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME.

Expert opinion

To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Regio

SUBMITTER: Schernthaner G 

PROVIDER: S-EPMC6580491 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature